Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)-Reference-Cited by-同舟云学术

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

Published:2017-01-24 Issue:2 Volume:79 Page:421-429
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Abou-Alfa Ghassan K.,Yen Chia-Jui,Hsu Chih-Hung,O’Donoghue Joseph,Beylergil Volkan,Ruan Shutian,Pandit-Taskar Neeta,Gansukh Bolorsukh,Lyashchenko Serge K.,Ma Jennifer,Wan Peter,Shao Yu-Yun,Lin Zhong-Zhe,Frenette Catherine,O’Neil Bert,Schwartz Lawrence,Smith-Jones Peter M.,Ohtomo Toshihiko,Tanaka Takayoshi,Morikawa Hideo,Maki Yuko,Ohishi Norihisa,Chen Ya-Chi,Agajanov Tamara,Boisserie Frederic,Di Laurenzio Laura,Lee Ray,Larson Steven M.,Cheng Ann-Lii,Carrasquilo Jorge A.

Funder

F. Hoffmann-La Roche

Chugai

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-017-3241-9.pdf

Reference15 articles.

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34